LRRK2 looming larger

Researchers from the University of Pittsburgh have identified a link between LRRK2 activity and idiopathic forms of Parkinson’s disease, further broadening the potential patient population for LRRK2 inhibitors in development, including two clinical compounds from Denali Therapeutics Inc. (NASDAQ: DNLI).

Multiple gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) have been implicated in autosomal dominant forms of Parkinson’s disease. However, the role of LRRK2 in the larger idiopathic PD patient population has been unclear...